AnaptysBio, Inc. (NASDAQ:ANAB) Receives $41.45 Consensus Target Price from Brokerages

Shares of AnaptysBio, Inc. (NASDAQ:ANAB) have been given an average rating of “Moderate Buy” by the twelve brokerages that are covering the company, MarketBeat Ratings reports. Four research analysts have rated the stock with a hold recommendation and eight have assigned a buy recommendation to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $41.45.

Several analysts recently commented on the stock. Guggenheim reduced their price objective on shares of AnaptysBio from $90.00 to $36.00 and set a “buy” rating for the company in a research note on Thursday, December 12th. JPMorgan Chase & Co. reduced their price target on shares of AnaptysBio from $66.00 to $36.00 and set an “overweight” rating for the company in a research report on Thursday, December 19th. UBS Group upped their price target on AnaptysBio from $23.00 to $33.00 and gave the stock a “neutral” rating in a report on Wednesday, October 30th. HC Wainwright cut AnaptysBio from a “buy” rating to a “neutral” rating and reduced their price objective for the stock from $52.00 to $19.00 in a report on Wednesday, December 11th. Finally, Wedbush reissued an “outperform” rating and issued a $40.00 target price (down previously from $42.00) on shares of AnaptysBio in a report on Wednesday, December 11th.

AnaptysBio Trading Down 3.2 %

Shares of ANAB stock opened at $14.36 on Monday. The stock has a 50 day simple moving average of $18.97 and a 200-day simple moving average of $28.30. The company has a market cap of $436.96 million, a price-to-earnings ratio of -2.36 and a beta of -0.02. AnaptysBio has a 12-month low of $12.51 and a 12-month high of $41.31.

AnaptysBio (NASDAQ:ANAB) last released its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($1.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.72) by $0.58. The firm had revenue of $30.02 million during the quarter, compared to analysts’ expectations of $7.92 million. AnaptysBio had a negative return on equity of 287.94% and a negative net margin of 289.75%. On average, equities analysts forecast that AnaptysBio will post -6.02 earnings per share for the current fiscal year.

Insider Activity at AnaptysBio

In other news, Director Ecor1 Capital, Llc bought 65,184 shares of the firm’s stock in a transaction that occurred on Monday, December 30th. The shares were purchased at an average price of $12.92 per share, for a total transaction of $842,177.28. Following the completion of the transaction, the director now owns 7,860,180 shares in the company, valued at $101,553,525.60. The trade was a 0.84 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 33.70% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. Bank of New York Mellon Corp lifted its holdings in shares of AnaptysBio by 16.3% during the 2nd quarter. Bank of New York Mellon Corp now owns 74,510 shares of the biotechnology company’s stock worth $1,867,000 after acquiring an additional 10,423 shares during the period. Rhumbline Advisers raised its stake in AnaptysBio by 1.8% during the second quarter. Rhumbline Advisers now owns 29,715 shares of the biotechnology company’s stock worth $745,000 after purchasing an additional 525 shares during the period. TD Asset Management Inc boosted its holdings in shares of AnaptysBio by 67.3% in the 2nd quarter. TD Asset Management Inc now owns 37,800 shares of the biotechnology company’s stock valued at $947,000 after purchasing an additional 15,200 shares during the last quarter. Headlands Technologies LLC grew its stake in shares of AnaptysBio by 444.8% during the 2nd quarter. Headlands Technologies LLC now owns 3,552 shares of the biotechnology company’s stock valued at $89,000 after buying an additional 2,900 shares during the period. Finally, Renaissance Technologies LLC increased its holdings in shares of AnaptysBio by 52.4% during the 2nd quarter. Renaissance Technologies LLC now owns 152,702 shares of the biotechnology company’s stock worth $3,827,000 after buying an additional 52,502 shares during the last quarter.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.